NOVAVAX INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $682.2M | $983.7M | $2.0B | $1.1B |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M | -$1.7B |
| Cost of revenue | $73.0M | $202.7M | $343.8M | $902.6M | $0 |
| Cash from operations | -$244.6M | -$87.3M | -$714.0M | -$415.9M | $322.9M |
| Capital expenditure | $0 | $1.1M | $7.9M | $17.7M | $57.5M |
| Free cash flow | -$244.6M | -$88.3M | -$721.9M | -$433.6M | $265.5M |
| Impairments | $0 | $4.1M | $10.1M | $0 | $0 |
| Total assets | $1.2B | $1.6B | $1.8B | $2.3B | $2.6B |
| Total liabilities | $1.3B | $2.2B | $2.5B | $2.9B | $2.9B |
Shares outstanding 164.4M · Free float 77.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.